Citius Pharmaceuticals (CTXR) Change in Interest Receivables (2013 - 2023)
Citius Pharmaceuticals' (CTXR) quarterly Change in Interest Receivables came in at -$551538.0 in Q3 2023, down 13.78% YoY from -$639670.7 in Q3 2022, and up 4.85% on a QoQ basis from -$579668.0 in Q2 2023.
Citius Pharmaceuticals (CTXR) Change in Interest Receivables (2013 - 2023) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 11 years of Change in Interest Receivables data on file, last reported at -$551538.0 in Q3 2023.
- Quarterly Change in Interest Receivables fell 13.78% year-over-year to -$551538.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$394732.0 (down 374.6% YoY) and the FY2023 annual result came in at -$394732.0, down 374.6% from the prior year.
- Change in Interest Receivables climbed to -$551538.0 in Q3 2023, from -$579668.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $1.4 million in Q1 2022 to a low of -$579668.0 in Q2 2023.
- A 5-year average of -$10616.7 and a median of -$4121.5 in 2019 frame the typical range for Change in Interest Receivables.
- Annual changes were most pronounced in 2021 — Change in Interest Receivables slumped 8158.32% — and 2022, when it jumped 36668.67%.
- Tracing CTXR's Change in Interest Receivables over 5 years: stood at -$3991.0 in 2019, then rose by 0.58% to -$3968.0 in 2020, then tumbled by 8158.32% to -$327690.0 in 2021, then dropped by 5.21% to -$344763.0 in 2022, then plunged by 59.98% to -$551538.0 in 2023.
- The last three Change in Interest Receivables figures came in at -$551538.0 (Q3 2023), -$579668.0 (Q2 2023), and $1.1 million (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -551,538.00 |
| Jun 30, 2023 | -579,668.00 |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | -344,763.00 |
| Sep 30, 2022 | -484,750.00 |
| Jun 30, 2022 | -484,251.00 |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | -327,690.00 |
| Jun 30, 2021 | 95,903.00 |
| Mar 31, 2021 | -3,939.00 |
| Dec 31, 2020 | -3,968.00 |
| Sep 30, 2020 | -3,457.00 |
| Jun 30, 2020 | -4,245.00 |
| Mar 31, 2020 | -3,980.00 |
| Dec 31, 2019 | -3,991.00 |
| Sep 30, 2019 | -4,197.00 |
| Jun 30, 2019 | -4,138.00 |
| Mar 31, 2019 | -4,105.00 |
| Dec 31, 2018 | -4,003.00 |
| Sep 30, 2018 | -3,848.00 |